Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

Hepatitis B Virus Clinical Trial

Official title:

A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00805675
• Other study ID #: CLDT600AHK01
• Status: Completed
• Phase: Phase 3
• First received: December 9, 2008
• Last updated: January 26, 2012
• Start date: November 2008

Study information

• Verified date: January 2012
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs. tenofovir DF 300 mg once daily (QD) or vs telbivudine 600 mg monotherapy daily (QD). This is an open labeled, active controlled, viral kinetics study which means the subjects and study doctor will know what study drug subjects have been assigned. This study is open to male and female subjects, <40 years of age, who have been infected with HBV for at least 6 months and have not received oral treatment for HBV.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Chronic HBV infection, defined as positive serum HBsAg for at least 6 months, or HBsAg positive > 3 months and negative for IgM anti-HBc and positive for IgG anti-HBc

• Age < 40 years old

• HBeAg positive

• HBV DNA > or = to 10^7 copies/mL by Abbott real-time PCR

• ALT < or = to 1 ULN

• Willing and able to provide written informed consent

• No prior oral HBV therapy (e.g., nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)

• Is willing and able to comply with the study drug regimen and all other study procedures and requirements

• Is willing and able to provide written informed consent before any study assessment is perform

Exclusion Criteria:

• Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 × ULN, PT > 1.2 × ULN, platelets < 150,000/mm3, serum albumin < 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g. ascites, jaundice, encephalopathy, variceal hemorrhage).

• Received interferon (pegylated or not) therapy within 6 months of the screening visit

• a-fetoprotein > 50 ng/mL

• Evidence of hepatocellular carcinoma (HCC)

• Co-infection with HCV (by serology), or HIV,

• Significant renal, cardiovascular, pulmonary, or neurological disease.

• Received solid organ or bone marrow transplantation.

• Is currently receiving therapy with immunomodulators (e.g., corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion.

• Has proximal tubulopathy.

• Use of other investigational drugs at the time of enrollment, or within 30 days

• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes

• Is pregnant or breastfeeding.

• Is a women of child-bearing potential (WOCBP)unless post-menopausal or using one or more acceptable method of contraception.

• Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.

• Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.

• Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B Virus

Intervention

Drug:
• Telbivudine
600 mg monotherapy supplied in film-coated tablets.
• Tenofovir
Tenofovir disoproxil fumarate was supplied in 300 mg tablets
• Telbivudine plus tenofovir
Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.

Locations

Country	Name	City	State
China	Department of Medicine, Queen Mary Hospital	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.	Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be = 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay.	Baseline, Week 12	No
Secondary	Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.	Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be = 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay.	Baseline, Week 2, Week 4, Week 8	No
Secondary	Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12	Polymerase Chain Reaction (PCR) Negative is defined as HBV DNA levels <25 copies/ml.	Week 12	No
Secondary	Percentage of Patients Who Achieve Hepatitis B "e" Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12	HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). HBeAg stands for hepatitis B "e" antigen. This antigen is a protein from the hepatitis B virus that circulates in infected blood when the virus is actively replicating. The presence of HBeAg suggests that the person is infectious and is able to spread the virus to other people.	Week 12	No
Secondary	Characterization of Very Early Viral Kinetics Through Estimated Viral Load	The underlying bi-phasic model of viral kinetics can be described as follows: V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss	Week 12	No
Secondary	Characterization of Very Early Viral Kinetics Through Viral Clearance	The underlying bi-phasic model of viral kinetics can be described as follows: V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss	Week 12	No
Secondary	Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss	The underlying bi-phasic model of viral kinetics can be described as follows: V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss	Week 12	No
Secondary	Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.	The underlying bi-phasic model of viral kinetics can be described as follows: V(t) (1 )pI(t) cV(t) I(t) (1 ) (T I(t))V(t) I(t) where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise allinfected and uninfected target cells, and d the rate of infected cell loss	Week 12	No
Secondary	Characterization of Very Early Viral Kinetics Through Half-live of Free Virus	The underlying bi-phasic model of viral kinetics can be described as follows: V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss	Week 12	No